Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Counterfeit Ovulen-21 case

Executive Summary

According to FDA's March/April Case News the last defendent in the counterfeiting case, Sheldon Harwin, was sentenced on May 1 in Miami Federal Court to "11 consecutive years of incarceration." On March 14, Harwin was found guilty on five counts, which include conspiracy, causing the printing of counterfeit labels, and distribution of a counterfeit drug, FDA said. A total of seven persons have been prosecuted by FDA for distributing counterfeit Ovulen-21, the agency said. Two other defendents that were found guilty in 1987 are serving sentences of 24 years apiece ("The Pink Sheet" Dec. 5, 1988, T&G-17).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel